Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill (TREATS Act / Telehealth Response for E-prescribing Addiction Therapy Services Act) amends the Controlled Substances Act to change the evaluation rules for prescribing certain controlled substances for substance use disorder (SUD) treatment. It requires at least one in-person medical evaluation and explicitly permits, for the purpose of prescribing FDA‑approved SUD treatments in Schedules III, IV, or V, a telehealth evaluation.
Access vs. safety: progressives emphasize improved access and harm reduction; conservatives emphasize diversion and public-safety risks.
Relative to its intended legislative type, this bill is a focused substantive statutory amendment that permissively expands telehealth as an option for prescribing certain FDA‑approved SUD medications by adding narrowly targeted language and a definition of telehealth evaluation.
The bill (TREATS Act / Telehealth Response for E-prescribing Addiction Therapy Services Act) amends the Controlled Substances Act to change the evaluation rules for prescribing certain controlled substances for substance use disorder (SUD) treatment.
It requires at least one in-person medical evaluation and explicitly permits, for the purpose of prescribing FDA‑approved SUD treatments in Schedules III, IV, or V, a telehealth evaluation.
The bill also defines “telehealth evaluation” to include two-way, real-time interactive communications meeting the Social Security Act section 1834(m) standard and explicitly allows audio-only or audio-and-video interactions.
On content alone, the bill is a modest, administratively focused change that reduces access barriers to FDA‑approved SUD medications via telehealth and preserves an in‑person evaluation requirement, which tends to make such measures more politically palatable. Its low fiscal impact and narrow scope favor passage, but the sensitive nature of controlled‑substance prescribing and potential regulatory concerns (including audio‑only provisions) create nontrivial opposition risk and potential demands for amendments or oversight, lowering the baseline probability compared with entirely noncontroversial technical fixes.
Relative to its intended legislative type, this bill is a focused substantive statutory amendment that permissively expands telehealth as an option for prescribing certain FDA‑approved SUD medications by adding narrowly targeted language and a definition of telehealth evaluation.
Access vs. safety: progressives emphasize improved access and harm reduction; conservatives emphasize diversion and public-safety risks.
These are examples from the analysis, not a ranked list of the most-affected groups.
Access vs. safety: progressives emphasize improved access and harm reduction; conservatives emphasize diversion and public-safety risks.
This persona is likely to view the bill positively as a targeted expansion of access to evidence-based SUD treatment.
By allowing telehealth (including audio-only) for prescribing FDA‑approved Schedule III–V medications, it reduces geographic and transportation barriers that disproportionately affect low-income, rural, and otherwise underserved patients.
They would welcome the emphasis on treatment access while noting that the requirement for at least one in-person evaluation keeps a safety floor.
A centrist would see the bill as a pragmatic, incremental change to expand treatment access while retaining an in-person evaluation requirement.
They will appreciate the balance between access and a safety baseline but will be cautious about possible unintended consequences such as diversion, enforcement complexity, and state-federal conflicts.
Overall they will be cautiously supportive if the bill includes clear implementation rules, evaluation metrics, and funding or coordination for oversight.
This persona would be skeptical of loosening controls on prescriptions for controlled substances and concerned about public safety and diversion.
While sympathetic to expanding treatment for the opioid crisis—especially in rural areas—they will worry that permitting telehealth (particularly audio-only) to substitute for in-person evaluation undermines safeguards in the Controlled Substances Act and complicates law enforcement.
Support would be conditional on strong verification, monitoring, and state flexibility, and some conservatives may oppose the bill without such safeguards.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a modest, administratively focused change that reduces access barriers to FDA‑approved SUD medications via telehealth and preserves an in‑person evaluation requirement, which tends to make such measures more politically palatable. Its low fiscal impact and narrow scope favor passage, but the sensitive nature of controlled‑substance prescribing and potential regulatory concerns (including audio‑only provisions) create nontrivial opposition risk and potential demands for amendments or oversight, lowering the baseline probability compared with entirely noncontroversial technical fixes.
The bill has not accumulated any surfaced votes yet.
Access vs. safety: progressives emphasize improved access and harm reduction; conservatives emphasize diversion and public-safety risks.
On content alone, the bill is a modest, administratively focused change that reduces access barriers to FDA‑approved SUD medications via te…
Relative to its intended legislative type, this bill is a focused substantive statutory amendment that permissively expands telehealth as an option for prescribing certain FDA‑approved SUD medications by adding narrowly…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.